Literature DB >> 21653760

Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.

Hana M El Sahly1, Larry D Teeter, Kenneth C Jost, Denise Dunbar, Justin Lew, Edward A Graviss.   

Abstract

Comprehensive data on the prevalence of quinolone resistance in Mycobacterium tuberculosis clinical isolates in the United States are scarce. By use of a systematic population-based approach, M. tuberculosis strains from tuberculosis (TB) cases were collected in Harris County, TX, in 2007 to 2008. The susceptibilities of M. tuberculosis isolates to moxifloxacin and ofloxacin were determined by the agar proportion indirect susceptibility method. Spoligotyping and 12-locus mycobacterial interspersed repetitive unit (MIRU12)-based genotyping of M. tuberculosis isolates were performed, and the gyrA, gyrB, Rv2686c, Rv2687c, and Rv2688c genes in quinolone-resistant and year-of-diagnosis-matched M. tuberculosis isolates were sequenced. Susceptibility testing was performed on 557 M. tuberculosis isolates, of which 10 (1.8%) were resistant to moxifloxacin. There was 100% concordance between ofloxacin and moxifloxacin susceptibilities. A quinolone was prescribed to at least 5 (50%) patients in the period preceding TB diagnosis. Multidrug-resistant TB (MDR-TB) was significantly associated with quinolone resistance (P = 0.01). Mutations in the quinolone resistance-determining region of gyrA were found for 50% of the resistant isolates. No other presumptive quinolone resistance-associated mutations were identified. We conclude that the incidence of moxifloxacin-resistant TB is low in Harris County and is associated with MDR-TB. Previous exposure to quinolones is common among patients with moxifloxacin resistance and warrants more careful evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653760      PMCID: PMC3147712          DOI: 10.1128/JCM.00231-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

3.  Drug-sensitivity profile of clinical Mycobacterium tuberculosis isolates--a retrospective study from a chest-disease institute in India.

Authors:  T Dam; M Isa; M Bose
Journal:  J Med Microbiol       Date:  2005-03       Impact factor: 2.472

4.  Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.

Authors:  E R Grimaldo; T E Tupasi; A B Rivera; M I Quelapio; R C Cardaño; J O Derilo; V A Belen
Journal:  Int J Tuberc Lung Dis       Date:  2001-06       Impact factor: 2.373

5.  In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.

Authors:  S Sulochana; F Rahman; C N Paramasivan
Journal:  J Chemother       Date:  2005-04       Impact factor: 1.714

Review 6.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates.

Authors:  Zhaogang Sun; Jianyuan Zhang; Xuxia Zhang; Sumin Wang; Ying Zhang; Chuanyou Li
Journal:  Int J Antimicrob Agents       Date:  2007-12-27       Impact factor: 5.283

8.  Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?

Authors:  K C Chang; C C Leung; W W Yew; T Y Lau; W M Leung; C M Tam; H C Lam; P S Tse; M Y Wong; S N Lee; K I Wat; Y H Ma
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

9.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

10.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

Authors:  Marcus B Conde; Anne Efron; Carla Loredo; Gilvan R Muzy De Souza; Nadja P Graça; Michelle C Cezar; Malathi Ram; Mohammad A Chaudhary; William R Bishai; Afranio L Kritski; Richard E Chaisson
Journal:  Lancet       Date:  2009-04-04       Impact factor: 79.321

View more
  5 in total

1.  Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.

Authors:  Christine Bernard; Nicolas Veziris; Florence Brossier; Wladimir Sougakoff; Vincent Jarlier; Jérôme Robert; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

2.  Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Authors:  Noton K Dutta; Abdullah Alsultan; Thomas J Gniadek; Deborah A Belchis; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Charles A Peloquin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

Review 3.  Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.

Authors:  Elisea Avalos; Donald Catanzaro; Antonino Catanzaro; Theodore Ganiats; Stephanie Brodine; John Alcaraz; Timothy Rodwell
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India.

Authors:  Vibhuti Rana; Nittu Singh; Chaitali Nikam; Priti Kambli; Pravin K Singh; Urmila Singh; Amita Jain; Camilla Rodrigues; Charu Sharma
Journal:  Infect Drug Resist       Date:  2022-04-08       Impact factor: 4.003

5.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Authors:  L Rigouts; N Coeck; M Gumusboga; W B de Rijk; K J M Aung; M A Hossain; K Fissette; H L Rieder; C J Meehan; B C de Jong; A Van Deun
Journal:  J Antimicrob Chemother       Date:  2015-11-24       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.